OBJECTIVE: To investigate the association between activity during interferon-beta (IFNβ) therapy and disability outcomes in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: A longitudinal study based on two previously described cohorts of IFNβ-treated RRMS patients was conducted. Patients were classified according to clinical activity after 2 years (clinical cohort) or to clinical and radiological activity after 1 year (magnetic resonance imaging (MRI) cohort). Multivariate Cox models were calculated for early disease activity predicting long-term disability. RESULTS: A total of 516 patients from two different cohorts were included in the analyses. Persistent clinical disease activity during the first 2 years of therapy predicted severe long-term disability (clinical cohort). In the MRI cohort, modified Rio score and no or minimal evidence of disease activity (NEDA/MEDA) did not identify patients with risk of Expanded Disability Status Scale (EDSS) worsening. However, a Rio score ≥ 2 (hazard ratio (HR): 3.3, 95% confidence interval (CI): 1.7-6.4); ≥3 new T2 lesions (HR: 2.9, 95% CI: 1.5-5.6); or ≥2 Gd-enhancing lesions (HR: 2.1, 95% CI: 1.1-4) were able to identify patients with EDSS worsening. CONCLUSION: Although early activity during IFNβ therapy is associated with poor long-term outcomes, minimal degree of activity does not seem to be predictive of EDSS worsening over 6.7-year mean follow-up.
OBJECTIVE: To investigate the association between activity during interferon-beta (IFNβ) therapy and disability outcomes in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: A longitudinal study based on two previously described cohorts of IFNβ-treated RRMS patients was conducted. Patients were classified according to clinical activity after 2 years (clinical cohort) or to clinical and radiological activity after 1 year (magnetic resonance imaging (MRI) cohort). Multivariate Cox models were calculated for early disease activity predicting long-term disability. RESULTS: A total of 516 patients from two different cohorts were included in the analyses. Persistent clinical disease activity during the first 2 years of therapy predicted severe long-term disability (clinical cohort). In the MRI cohort, modified Rio score and no or minimal evidence of disease activity (NEDA/MEDA) did not identify patients with risk of Expanded Disability Status Scale (EDSS) worsening. However, a Rio score ≥ 2 (hazard ratio (HR): 3.3, 95% confidence interval (CI): 1.7-6.4); ≥3 new T2 lesions (HR: 2.9, 95% CI: 1.5-5.6); or ≥2 Gd-enhancing lesions (HR: 2.1, 95% CI: 1.1-4) were able to identify patients with EDSS worsening. CONCLUSION: Although early activity during IFNβ therapy is associated with poor long-term outcomes, minimal degree of activity does not seem to be predictive of EDSS worsening over 6.7-year mean follow-up.
Authors: Claudio Gasperini; Luca Prosperini; Mar Tintoré; Maria Pia Sormani; Massimo Filippi; Jordi Rio; Jacqueline Palace; Maria A Rocca; Olga Ciccarelli; Frederik Barkhof; Jaume Sastre-Garriga; Hugo Vrenken; Jette L Frederiksen; Tarek A Yousry; Christian Enzinger; Alex Rovira; Ludwig Kappos; Carlo Pozzilli; Xavier Montalban; Nicola De Stefano Journal: Neurology Date: 2018-12-26 Impact factor: 9.910
Authors: L Danieli; L Roccatagliata; D Distefano; E Prodi; G C Riccitelli; A Diociasi; L Carmisciano; A Cianfoni; T Bartalena; A Kaelin-Lang; C Gobbi; C Zecca; E Pravatà Journal: AJNR Am J Neuroradiol Date: 2022-05-26 Impact factor: 4.966
Authors: Thomas Lehnert; Christian Röver; Sascha Köpke; Jordi Rio; Declan Chard; Andrea V Fittipaldo; Tim Friede; Christoph Heesen; Anne C Rahn Journal: Syst Rev Date: 2022-07-01
Authors: Francisco Coret; Francisco C Pérez-Miralles; Francisco Gascón; Carmen Alcalá; Arantxa Navarré; Ana Bernad; Isabel Boscá; Matilde Escutia; Sara Gil-Perotin; Bonaventura Casanova Journal: Mult Scler J Exp Transl Clin Date: 2018-06-26
Authors: Jaume Sastre-Garriga; Deborah Pareto; Marco Battaglini; Maria A Rocca; Olga Ciccarelli; Christian Enzinger; Jens Wuerfel; Maria P Sormani; Frederik Barkhof; Tarek A Yousry; Nicola De Stefano; Mar Tintoré; Massimo Filippi; Claudio Gasperini; Ludwig Kappos; Jordi Río; Jette Frederiksen; Jackie Palace; Hugo Vrenken; Xavier Montalban; Àlex Rovira Journal: Nat Rev Neurol Date: 2020-02-24 Impact factor: 42.937
Authors: Ellen Iacobaeus; Georgina Arrambide; Maria Pia Amato; Tobias Derfuss; Sandra Vukusic; Bernhard Hemmer; Mar Tintore; Lou Brundin Journal: Mult Scler Date: 2020-06-12 Impact factor: 6.312